menu
    • menu
    [{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BBP-711","moa":"2-Hydroxyacid oxidase 1 (HAO1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ALXN2050","moa":"Complement factor B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicopan","moa":"Complement factor D","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ALXN2080","moa":"Complement factor D (CFD)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Concert Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Oppilan Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Arthrosi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C AR882","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"2217LS","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Alexza Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZ-010","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Enlicitide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NO-13065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PORT-77","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Immunology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PRA023","moa":"Vascular endothelial cell growth inhibitor (TNFSF15)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"}]

    Find Clinical Drug Pipeline Developments & Deals by MTS Health Investors, LLC

    Menu

    MTS Health Investors, LLC

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PORT-77

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Portal Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

                            Details : PORT-77 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Protoporphyria, Erythropoietic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : PORT-77

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Portal Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levothyroxine Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

                            Details : Levothyroxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            October 03, 2024

                            Lead Product(s) : Levothyroxine Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enlicitide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Partici...

                            Details : Enlicitide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Enlicitide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALXN2080

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

                            Details : ALXN2080 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 23, 2022

                            Lead Product(s) : ALXN2080

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Recipient : Veralox Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

                            Details : VLX-1005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 13, 2022

                            Lead Product(s) : VLX-1005

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Recipient : Veralox Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : BioLineRx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

                            Details : BL-8040 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 24, 2022

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : BioLineRx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

                            Details : Acoramidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Acoramidis Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBP-711

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Cantero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

                            Details : BBP-711 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2021

                            Lead Product(s) : BBP-711

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Cantero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2217LS

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : MassBiologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disea...

                            Details : 2217LS is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lyme Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 28, 2021

                            Lead Product(s) : 2217LS

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : MassBiologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NO-13065

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : Otsuka Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese...

                            Details : NO-13065 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2021

                            Lead Product(s) : NO-13065

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : Otsuka Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth